Real World Evidence / HEOR Publication List

Publications as of June 2018
HEOR publications

Journal articles


Conference abstracts


39. Doshi G, Bhanegaonkar A, Bharmal M, Phatak H, Aguilar K, Kearney M. SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR): first- through third-line time to treatment failure in the US. ASCO; June 1-5, 2018; Chicago, IL.


42. Bookman MA, Espirito JL, Wilson T, Fernandes A. Chemotherapy costs, but not resource utilization, are inversely correlated with the primary platinum-free interval among outpatients with recurrent ovarian cancer. Society of Gynecologic Oncology Annual Meeting; March 15-17, 2017.

43. Cartwright T, Parisi M, Espirito JL, Wilson T, Pelletier C, Patel M, Babiker HM. Treatment outcomes with first-line (1L) nab-Paclitaxel + gemcitabine (AG) and FOLFIRINOX (FFX) in metastatic pancreatic adenocarcinoma ASCO; June 2-6, 2017; Chicago, IL.

44. Cowey CL, Liu FX, Black-Shinn J, Stevinson K, Boyd M, Patt D, Ebbinghaus S. An Observational Study of Patients with Advanced Melanoma Receiving Pembrolizumab in Real World US Community Oncology Practice ASCO; June 2-6, 2017; Chicago, IL.


46. Nadler E, Joo S, Black-Shinn J, Boyd M, Zhuo J, Chirovsky D. Treatment patterns in recurrent/metastatic head and neck squamous cell carcinoma in the US. ASCO; June 2-6, 2017; Chicago, IL.


49. Flannery K, Black-Shinn J, Boyd M, Kamat A. Real world treatment utilization and outcomes of patients with metastatic bladder cancer by cisplatin eligibility in US community oncology practice. ASCO; June 2-6, 2017; Chicago, IL.


52. Sharman J, Black-Shinn J, Clark J, Bitman B. Understanding Ibrutinib Treatment Discontinuation Patterns for Chronic Lymphocytic Leukemia. ASH Annual Meeting; Dec 9-12, 2017; Atlanta, CA.

53. Sharman J, Black-Shinn J, Clark J, Karve S. MCL Treatment Patterns and Outcomes: A Community Oncology Practice Experience. ASH Annual Meeting; Dec 9-12, 2017; Atlanta, CA.


58. Cowey CL. Real-world outcomes of patients with metastatic merkel cell carcinoma treated with second-line or later chemotherapy in a community oncology setting in the United States. ISPOR Annual European Congress Oct. 29 - Nov. 2, 2016; Vienna, Austria.


60. Bookman MA, Tyczynski JE, Espirito JL, Wilson T, Fernandes A. Sustained impact of primary platinum-free interval and BRCA1/2 mutation status on survival in patients with ovarian cancer after multiple lines of therapy. ASCO; Jun 3-7, 2016; Chicago, IL.


66. Patt D, Fonseca E, Yoo B, Wilson T, Goertz HP, Lai C. Real world treatment patterns and outcomes in HER2 positive MBC patients with brain metastasis in the US community oncology setting. ASCO Quality Care Symposium; Feb 26-27, 2016; Phoenix, AZ.


68. Robert N, Goertz HP, Chopra P, Jiao X, Yoo B, Patt D, Antao V. Clinical characteristics, treatment patterns, and outcomes for patients with HER2-positive metastatic breast cancer treated with pertuzumab in the first-line in a real-world setting. European Cancer Congress; Sept 25-29, 2015; Vienna, Austria.

69. Rifkin RM, Fonseca E, Chen YJ, Fox PS, Browning JE, Cong Z. Carfilzomib dosing patterns and survival in patients with relapsed and refractory multiple myeloma: an analysis from US community oncology practices. Annual Meeting of the American Society of Hematology; Dec. 5-8, 2015; Orlando, FL.

70. Robert N, Goertz HP, Jiao X, Yoo B, Patt D, Antao V. Pertuzumab (P) use in first-line HER2-positive metastatic breast cancer (mBC) in US community oncology practices: Treatment patterns and outcomes. San Antonio Breast Cancer Symposium; Dec 8-12, 2015; San Antonio, TX.

71. Hutson TE, Hackshaw MD, Vogelzang NJ, Bhowmik D, Yap M, Rembert D, Jonasch E. Outcomes of advanced renal cell carcinoma patients (aRCC) treated with mammalian target of rapamycin inhibitor (mTORi) therapy following first-line pazopanib (PAZ) in a US Community Oncology Setting. ESMO; Sept 26-30, 2014; Madrid, Spain.


73. Cartwright T, Pan I, Wen L, Wadlow RC, Rembert D, Seal B. Treatment patterns and outcomes in metastatic colorectal cancer (mCRC) patients treated in a community oncology setting. ISPOR Annual International Meeting; May 31-Jun4, 2014; Montreal, QC, Canada.


76. Patt D, Richardson P, Rembert D, Corzo D, Chen C. Treatment of patients (pts) with HER2- metastatic breast cancer (MBC) with nab-paclitaxel (nab-P) in the clinical practice setting—Results of a US Oncology survey. ASCO Annual Meeting; May 30 - June 3, 2014; Chicago, IL.

77. Kumar SK, Engebretson AE, Baudi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille M, Lefebvre P, Cheng W, Dea K, Yap M, Saravanan S, Pan I, Rembert D, Patt D, Niculescu L, Ma E, Quick M, Rajkumar SV. Comparable outcomes and lower total healthcare cost with bortezomib-cyclophosphamide-dexamethasone (VCD) compared to bortezomib-lenalidomide-dexamethasone (VRD) for initial treatment of newly diagnosed multiple myeloma (MM). Association for Value-Based Cancer Care May 6-9, 2014; Los Angeles, CA.

78. Kolibaba KS. Treatment response monitoring in chronic phase CML (CP-CML) patients receiving tyrosine kinase inhibitor (TKI) therapy in US Oncology network. ASCO Annual Meeting; May 31-Jun 4, 2013; Chicago, IL.


82. Chen C, Chen L, Dhanda R, Chung H, Bhowmilk D, Ericson S, DiBella N. Types, frequency, and adherence of molecular tests in chronic myelogenous leukemia at chronic phase (CML-CP) in the U.S. community setting. ASCO Annual Meeting; May 31- Jun 4, 2013; Chicago, IL.


91. Rifkin RM, Chen C, Dhanda R, Rembert D, Ba-Mancini A, Ma E, Zhu Y, Dow E, Niculescu L. Impact of route of bortezomib (B) administration on dose intensity and time to dose reduction in previously untreated patients (pts) With multiple myeloma (MM). Annual Meeting of the American Society of Hematology; Dec 7-10, 2013; New Orleans, LA.


94. Chen C, Borker R, Dhanda R, Nadler E. Treatment practice patterns and survival among patients with metastatic soft tissue sarcoma (mSTS) in a community setting in the United States. ASCO Annual Meeting; Jun 1-5, 2012; Chicago, IL.


96. Nadler E, Sail K, Chen C, Thompson JA, Kolodziej M. Retrospective observational study: Bevacizumab (B) use and outcomes among metastatic colorectal cancer (mCRC) patients (pts) receiving care in the outpatient community in the United States. Gastrointestinal Cancers Symposium; Jan 19-21, 2012; San Francisco, CA.


100. Chen C, Patt D, Kazzaz DR, Shankleton JA, Forsyth M, Ganesh R. Evaluating utilization characteristics for the Oncotype DX recurrence score in early-stage breast cancer. ASCO Annual Meeting; Jun 3-7, 2011; Chicago, IL.


102. Joshi AD, Forsyth M, Fryefield DC, Lopez W, Chen DM, Ramanan DD. Demographic and treatment characteristics for advanced basal cell carcinoma (aBCC) in an oncology outpatient setting. ASCO Annual Meeting; Jun 3-7, 2011; Chicago, IL.


106. Sail K, Lalla D, Brammer M, Halm M, Patt D. Treatment patterns in patients with HER2-positive early-stage breast cancer (ESBC) receiving adjuvant treatment with a trastuzumab-containing regimen. ASCO Annual Meeting; Jun 3-7, 2011; Chicago, IL.

107. Sharma PP, Sail K, Delea TE, Forsyth M, Halm M, Nagarwala M, Lopez W, Patt D. Patterns of care and patient characteristics in postmenopausal women with HER2+ and hormone receptor-positive (HR+) metastatic breast cancer (MBC). ASCO Annual Meeting; Jun 3-7, 2011; Chicago, IL.


110. Brammer M, Gruschkus S, Lalla D, Doan JF, Forsyth M. HER2 status and trastuzumab use among patients with early breast cancer receiving care within the US Oncology network. ESMO; Oct 8-12, 2010; Milan, Italy.

111. Ravelo A, Nadler E, Yu E, Sing A, Forsyth M, Gruschkus S. Bevacizumab (BV) treatment (Tx) to progression (BTP): outcomes from a US community practice network. ESMO; Oct 8-12, 2010; Milan, Italy.

112. Gruschkus S, Reyes C, Forsyth M, Nadler E, Ravelo A. Economic outcomes among 2nd line non-small cell lung cancer patients in the outpatient community setting. ISPOR Annual European Congress; Nov 6-9, 2010; Prague, Czech Republic.

113. Hoverman JR, Pohl G, Gruschkus S, Marciniak M, Forsyth M, Peltz G. Cost-effectiveness of 1st line chemotherapy regimens in the treatment of NSCLC among patients receiving care in the outpatient community setting. ISPOR; May 15-19, 2010; Atlanta, GA.


117. Gruschkus SK, Doan JF, Chen C, Forsyth M, Lalla D, Shing M. First-line patterns of care and outcomes of HER2-positive breast cancer patients who progressed after receiving adjuvant trastuzumab in the outpatient community setting. ASCO Annual Meeting; Jun 4-8, 2010; Chicago, IL.

118. Neubauer M, Espirito JL, Clayton GC, Patt D. Combination versus sequential chemotherapy for metastatic breast cancer: An evaluation of outcomes from a community oncology network. ASCO Annual Meeting; Jun 4-8, 2010; Chicago, IL.


120. Gruschkus S, Darragh J, Forsyth M, Beveridge R, Reyes C. Economic impact of disease progression in follicular non-hodgkin’s lymphoma. American Society of Hematology Annual Meeting; Dec 4-7, 2010; Orlando, FL.


